In this context, it is interesting to note that heterotopic bone formation in different experimental models can be inhibited by 3 different RARγ agonists (52) and that the RARγ agonist palovarotene is now in clinical trials to prevent heterotopic bone formation in patients with the inherited disease fibrodysplasia ossificans progressiva (53). This evidence concerns the gene RARG and fibrodysplasia ossificans progressiva.